| Trial ID: | L3821 |
| Source ID: | NCT05498610
|
| Associated Drug: |
Nnc0480 0389
|
| Title: |
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: NNC0480 0389|DRUG: Semaglutide
|
| Outcome Measures: |
Primary: AUC0-∞,NNC0480-0389,SD Area under the NNC0480-0389 plasma concentration-time curve from time 0 to infinity after a single dose (SD), measured in hnmol\^L, From pre-dose (day 1) to completion of the post-dose follow-up visit (day 43)|Cmax,NNC0480-0389,SD Maximum plasma concentration of NNC0480-0389 after a single dose, measured in nmol/L, From pre-dose (day 1) to completion of the post-dose follow-up visit (day 43) | Secondary: AUC0-∞,sema,SD Area under the semaglutide plasma concentration-time curve from time 0 to infinity after a single dose, measured in hnmol\^L, From pre-dose (day 1) to completion of the post-dose follow-up visit (day 43)|Cmax,sema,SD The maximum plasma concentration of semaglutide after a single dose, measured in nmol\^L, From pre-dose (day 1) to completion of the post-dose follow-up visit (day 43)
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2022-08-11
|
| Completion Date: |
2022-10-12
|
| Results First Posted: |
|
| Last Update Posted: |
2023-12-26
|
| Locations: |
Novo Nordisk Investigational Site, Beijing, Beijing, 100730, China
|
| URL: |
https://clinicaltrials.gov/show/NCT05498610
|
